Efficacy and Safety of Drug-coated Balloon for De Novo Lesions of Large Coronary Arteries: Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Feb 9

PMID 38333846

Authors

Jin-Li Jiang

Qiao-Juan Huang

Meng-Hua Chen

Affiliations

Soon will be listed here.

Abstract

Background: Drug-coated balloon (DCB) is a novel approach to avoiding stent-related complications and has proven effective for the treatment of in-stent restenosis (ISR) and small vessels. However, its role in the treatment of de novo lesions in large vessels is less settled.

Aims: To estimate the efficacy and safety of drug-coated balloon versus stent in the treatment of de novo lesions in large coronary arteries.

Methods: We searched the literature until April 2023. We judged the safety of DCB based on major adverse cardiovascular events (MACEs), cardiac death, all-cause mortality, non-fatal myocardial infarction, target lesion revascularization (TLR), and bleeding event; and efficacy according to late lumen loss (LLL), minimum lumen diameter (MLD). We conducted subgroup analyses according to stent type and whether urgent PCI was required.

Results: A total of 10 RCTs were included. Overall, LLL (mean difference (MD) = -0.19, 95 % confidence interval (CI): -0.32 to -0.06, P = 0.003) was lower in the DCB group than in the Stent arm. This effect was consistent in subgroup analysis regardless of stent type and disease type. In terms of safety indicators, there were no significant differences between DCB and stent. The subgroup analyses found that safety indicators showed no significant differences between DCB and drug-eluting stent (DES), but TLR was lower in the DCB than in the bare metal stent (BMS). Moreover, in ST-elevation myocardial infarction (STEMI), safety indicators and LLL showed no significant differences between DCB and DES, but MLD in the DCB was smaller. While in patients with excluded STEMI, MACE and TLR was lower in the DCB compared with the overall stent.

Conclusions: DCB could be a promising alternative for treating de novo lesions in large coronary arteries with satisfactory efficacy and low risk, superior to BMS and not inferior to DES, with a trend toward lower late lumen loss.

References

Kleber F, Mathey D, Rittger H, Scheller B . How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011; 7 Suppl K:K125-8. DOI: 10.4244/EIJV7SKA21. View

Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E . Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. Atherosclerosis. 2021; 321:39-44. DOI: 10.1016/j.atherosclerosis.2021.02.006. View

Hoole S, Bambrough P . Recent advances in percutaneous coronary intervention. Heart. 2020; 106(18):1380-1386. DOI: 10.1136/heartjnl-2019-315707. View

Scheller B, Ohlow M, Ewen S, Kische S, Rudolph T, Clever Y . Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2019; 15(17):1527-1533. DOI: 10.4244/EIJ-D-19-00723. View

Gobic D, Tomulic V, Lulic D, Zidan D, Brusich S, Jakljevic T . Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study. Am J Med Sci. 2017; 354(6):553-560. DOI: 10.1016/j.amjms.2017.07.005. View

Sigwart U, Puel J, MIRKOVITCH V, Joffre F, Kappenberger L . Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987; 316(12):701-6. DOI: 10.1056/NEJM198703193161201. View

Sun K, Liu Z, Wang H . Drug-Coated Balloon vs. Stent for Non-small Coronary Artery Disease: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021; 8:700235. PMC: 8702625. DOI: 10.3389/fcvm.2021.700235. View

Nestelberger T, Kaiser C, Jeger R . Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. Expert Opin Drug Deliv. 2020; 17(2):201-211. DOI: 10.1080/17425247.2020.1714590. View

Li Q, Chang M, Wang X, Wang A, Liu Q, Wang T . Efficacy and safety of drug-coated balloon in the treatment of acute myocardial infarction: a meta-analysis of randomized controlled trials. Sci Rep. 2022; 12(1):6552. PMC: 9023471. DOI: 10.1038/s41598-022-10124-z. View

10.

Wang L, Li X, Li T, Liu L, Wang H, Wang C . Novel application of drug-coated balloons in coronary heart disease: A narrative review. Front Cardiovasc Med. 2023; 10:1055274. PMC: 10017483. DOI: 10.3389/fcvm.2023.1055274. View

11.

Elgendy I, Gad M, Elgendy A, Mahmoud A, Mahmoud A, Cuesta J . Clinical and Angiographic Outcomes With Drug-Coated Balloons for De Novo Coronary Lesions: A Meta-Analysis of Randomized Clinical Trials. J Am Heart Assoc. 2020; 9(10):e016224. PMC: 7660863. DOI: 10.1161/JAHA.120.016224. View

12.

Al-Lamee R, Foley M, Rajkumar C, Francis D . Revascularization in stable coronary artery disease. BMJ. 2022; 377:e067085. DOI: 10.1136/bmj-2021-067085. View

13.

Yerasi C, Case B, Forrestal B, Torguson R, Weintraub W, Garcia-Garcia H . Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(9):1061-1073. DOI: 10.1016/j.jacc.2019.12.046. View

14.

De Maria G, Alkhalil M, Oikonomou E, Wolfrum M, Choudhury R, Banning A . Role of deferred stenting in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention: A systematic review and meta-analysis. J Interv Cardiol. 2017; 30(3):264-273. DOI: 10.1111/joic.12380. View

15.

Farah A, Elgarhy M, Ohlow M, Wohrle J, Mangner N, Mobius-Winkler S . Efficacy and safety of drug-coated balloons according to coronary vessel size. A report from the BASKET-SMALL 2 trial. Postepy Kardiol Interwencyjnej. 2022; 18(2):122-130. PMC: 9421526. DOI: 10.5114/aic.2022.118528. View

16.

Hao X, Huang D, Wang Z, Zhang J, Liu H, Lu Y . Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. J Cardiothorac Surg. 2021; 16(1):178. PMC: 8215732. DOI: 10.1186/s13019-021-01525-8. View

17.

Kite T, Kurmani S, Bountziouka V, Cooper N, Lock S, Gale C . Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J. 2022; 43(33):3148-3161. PMC: 9433309. DOI: 10.1093/eurheartj/ehac213. View

18.

Jaffe R, Charron T, Puley G, Dick A, Strauss B . Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008; 117(24):3152-6. DOI: 10.1161/CIRCULATIONAHA.107.742312. View

19.

Lang X, Wang Y, Li W, Liu X, Zhao Y, Wang C . Appropriate Surrogate Endpoint in Drug-Coated Balloon Trials for Coronary Artery Diseases. Front Cardiovasc Med. 2022; 9:897365. PMC: 9256952. DOI: 10.3389/fcvm.2022.897365. View

20.

Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning A, Benedetto U . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 40(2):87-165. DOI: 10.1093/eurheartj/ehy394. View